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Summary 
Glial fibrillary acidic protein (GFAP) is an intermediate 
filament protein specifically expressed in astrocytes 
in the CNS. To examine the function of GFAP in vivo, 
the Gfap gene was disrupted by gene targeting in em- 
bryonic stem cells. Mice homozygous for the mutation 
were completely devoid of GFAP but exhibited normal 
development and showed no obvious anatomical ab- 
normalities in the CNS. When inoculated with infec- 
tious scrapie prions, the mutant mice exhibited neu- 
ropathological changes typical of prion diseases. 
Infectious prions accumulated in brains of the mutant 
mice to a degree similar to that in control littermates. 
These results suggest that GFAP is not essential for 
the morphogenesis of the CNS or for astrocyUc re- 
sponses against neuronal injury. The results argue 
against the hypothesis that GFAP plays a crucial role 
in the pathogenesis of prion diseases. 
Introduction 
Intermediate filament (IF) proteins are prominent compo- 
nents of the cytoskeleton and nuclear envelope of most 
eukaryotic cell types. IF proteins constitute an extremely 
large multigene family and are classified into the distinct 
sequence types I-V (for review, see Steinert and Roop, 
1988). The expression of IF proteins exhibits a high degree 
of cell-type specificity, such as keratins of types I and II 
in epithelial cells, neurofilaments of type IV in nerve cells, 
desmin of type III in muscle cells, vimentin of type III in 
various mesenchymal cells, and glial fibrillary acidic pro- 
tein (GFAP) of type III in astrocytes (for a review, see Stein- 
ert and Roop, 1988). The differential expression of IF 
proteins in different cell types implies that they have spe- 
cialized roles in the differentiation and function of these 
cells. The following evidence supports this concept. Injec- 
tion of antibodies against neurofilament-M subunit into 
Xenopus laevis embryos inhibits development of periph- 
eral nerve cells (Szaro et al., 1991). Transgenic mice that 
accumulate neu rofilament-L subunit exhibit axonal degen- 
eration and severe skeletal muscle atrophy (Xu et al., 
1993). A mutant strain of the Japanese quail, quiver, which 
lacks neurofilaments, has the clinical feature of general- 
ized quivering and the morphological feature of decrease 
in size of myelinated axons (Yamasaki et al., 1991). Keratin 
depletion in Xenopus embryos by either antisense oligo- 
nucleotides or antibody injection prevents gastrulation 
(Klymkowsky et al., 1983; Torpey et al., 1992). Transgenic 
mice expressing a dominant-negative form of keratin 14 
suffered from skin abnormalities resembling a human ge- 
netic disease (Vassar et al., 1991). A null mutation in the 
keratin 8 gene, which is first expressed together with kera- 
tin 18 during embryogenesis, causes mid-gestational le- 
thality in mice (Baribault et al., 1993). 
Astrocytes fill the interstices between neuronal cell bod- 
ies and extend processes to ensheathe axons and blood 
vessels (Peters et al., 1991). Astrocytes are believed to be 
crucial for the nutritional and structural support of neurons 
and for the regulation of local concentrations of neuro- 
transmitters and ions. Other studies suggest that astrocytes 
have an inductive role in the formation of tight junctions 
between brain endothelia (Janzer and Raff, 1987; Arthur 
et al., 1987), contributing to the establishment of the blood- 
brain barrier (BBB) in vivo. The function of GFAP in 
astrocytes is largely unknown. Interestingly, removal of 
GFAP in a human astrocytoma cell line by transfection 
with an antisense construct caused an impaired ability of 
the cells to extend glial processes upon neuronal induction 
(Wei nstein et al., 1991), suggesting the necessity of GFAP 
for the formation of stable astrocytic processes in re- 
sponse to neurons. During development of the CNS, neu- 
rons are born on the ventricular surface of the neural tube 
and appear to migrate to their final destination along 
astrocytic processes (Rakic, 1972, 1981). Thus, it is pre- 
dicted that structural support of astrocytic processes by 
GFAP may be critical for the morphogenesis of the CNS. 
Astrocytes show remarkable cellular responses to a 
wide range of pathological conditions of the CNS. Astrocyte 
swelling, the Alzheimer type II response, and reactive 
astrocytosis (reactive gliosis) are examples of common 
astrocytic hanges (for review, see Norenberg, 1994). Re- 
active astrocytes are characterized histologically by cyto- 
plasmic hypertrophy associated with profusion of long and 
thick processes filled with GFAP, and by often enlarged 
and irregularly outlined nuclei. The astroglial scarring that 
frequently occurs under pathological conditions has also 
been interpreted as a process of repair and regeneration 
of the CNS (for review, see Reier and Houle, 1988). The 
hallmark of reactive astrocytosis is a prominent accumula- 
tion of GFAP (Eng, 1988). 
Prion diseases, such as scrapie in animals and Creutz- 
feldt-Jakob disease in humans, are transmissible neuro- 
degenerative disorders (spongiform encephalopathy) that 
cause typical reactive astrocytosis (Mackenzie, 1983; 
Weitgrefe et al., 1985; Manuelidis et al., 1987; BL~eler et 
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al., 1993). Thus, it is important to determine whether GFAP 
has a role in the pathogenesis of prion diseases. S. B. 
Prusiner proposed the "protein only" hypothesis in which 
the prion, the infectious agent, is PrP s°, a modified form 
of the normal host protein PrP c (Prusiner, 1982). Propaga- 
tion of the prion is ascribed to the conversion of PrP c into 
PrP s° under the influence of PrP s~ (Prusiner, 1991). This 
hypothesis has been confirmed directly by experiments 
utilizing mice devoid of PrP c generated by gene targeting 
(BLieler et al., 1993) and by experiments based on an in 
vitro cell-free system (Kocisko et al., 1994). However, it 
is not known whether any other molecule participates in 
either propagation of PrP s° or progression of the disease. 
Intriguing relationships between GFAP and infectious pri- 
ons have been observed. The progression of prion disease 
causes a typical reactive ast rocytosis along with increased 
GFAP expression (Weitgrefe et al., 1985; Manuelidis et 
al., 1987; B~eler et al., 1993). It has been suggested that 
high local concentrations of infectious Creutzfeldt-Jakob 
disease prion correlate with the level of Gfap mRNA ex- 
pression in astrocytes, rather than with the severity of the 
neuronal degeneration (Manuelidis et al., 1987). More- 
over, biochemical studies have revealed the specific bind- 
ing of PrP s~ to GFAP (Oesch et al., 1990). In this context, 
it is noteworthy that the conversion of PrP c to PrP s° and 
the accumulation of PrP s~ in astrocytes precede PrP s~ con- 
version and accumulation in neurons in the course of the 
disease (Diedrich et al., 1991). These observations ug- 
gested a potential role for GFAP in the pathogenesis of 
prion diseases. 
To address the function of GFAP in vivo, we used gene 
targeting to generate mutant mice in which the Gfap gene 
was disrupted by replacing it with the lacZ gene (Capecchi, 
1989). Our specific goals were to determine whether GFAP 
is crucial for the development of the CNS and whether 
GFAP participates in the pathogenesis of scrapie-induced 
encephalopathy. 
Results 
The Mutation of the Gfap Locus 
To generate a nu II mutation in the Gfap gene, we disrupted 
the first exon of the gene by gene targeting in embryonic 
stem (ES) cells. The targeting vector contains 5.5 kb of 
homologous sequences from the Gfap gene locus. The 
pgk-neo (McBurney et al., 1991) and MC1-DT-A (Yagi et 
al., 1990) gene cassettes were used as positive and nega- 
tive selection markers, respectively (Figure 1A). The pro- 
moterless/acZ, a reporter gene, was inserted just down- 
stream of the initiation codon of the Gfap gene in the sense 
orientation. Following homologous integration, this con- 
struct should express/acZ only at sites where the Gfap 
gene is normally transcriptionally active. The targeting 
vector was transfected into E14 ES cells (Hooper et al., 
1987) by electroporation. Of the 232 ES clones analyzed, 
25 were found to have the targeted mutation. 
Cells from 5 clones were injected into C57BL/6J blasto- 
cysts; 3 clones gave rise to germline chimeras. Inter- 
crosses between the heterozygotes (Gfap +j-) gave rise to 
homozygotes (Gfap+), Gfap +/-, and wild types (Gfap ÷l+) at 
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Figure 1. Targeted Disruption of the Gfap Gene with Insertion of the 
lacZ Gene 
(A) Schematic representations of the targeting vector, wild-type Gfap
locus, and mutant Gfap locus. The targeting vector used a neomycin 
resistance gene driven by the pgk promoter (pgk-neo) and a diphtheria 
toxin A-fragment gene (DT-A) driven by the MCl promoter as positive 
and negative selection markers, respectively. Exon structures (El- 
E9) are shown with open boxes. The crosses indicate the hypothetical 
crossovers between the targeting construct and the Gfap locus. Homol- 
ogous recombination results in replacement of the first exon of the 
Gfap gene with the lacZ gene and pgk-neo. The locations of the 5' 
external probe (5probe) and the 3 external probe (3 probe) are shown. 
The 5' probe hybridizes to a 4.0 kb Sacl fragment from the wild-type 
Gfap locus and to a 6.3 kb Sacl fragment from the mutated Gfap locus, 
and the 3' probe hybridizes to a 6.3 kb BamHI fragment from the 
wild-type Gfap locus and to a 4.5 kb BamHI fragment from the mutated 
Gfap locus. S, Sacl; B, BamHI. 
(B) Southern blot analysis of progeny from a cross of F1 heterozygotes. 
Genomic DNA was extracted from tail, digested, an  probed as de- 
scribed above. -/- ,  homozygotes; +/-, heterozygotes; +/+, wild type. 
(C) Immunoblot analysis of tissue extracts (10 pg) using a monoclonal 
anti-GFAP antibody. The monoclonal ntibody recognizes the 50 kDa 
GFAP in Gfap ÷/+ and Gfap */- mice but not in Gfap/- mice. CR, cere- 
brum; CB, cerebellum; SP, spinal cord. 
the expected frequency of 1:2:1. An example of Southern 
analysis of tail DNAs from this cross is shown in Figure 
lB. 
Mutant mice exhibit no striking behavioral changes and 
appear to have normal motor activity. The mutant mice 
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Figure 2. Histological Analysis of Gfap-"= and Gfap +1+ Mice 
Gfap-"- mutant (A, C, E, and G) and Gfap +~* (B, D, F, and H) mice. (A) and (B) show the hippocampal CA1 region in coronal sections labeled with 
an anti-GFAP monoclonal antibody; (C) and (D) show the expression of lacZ (C) or Gfap (D) in astrocytes induced by kainic acid treatment (KA). 
Kainic acid solubilized in phosphate-buffered saline (PBS) was administered intraperitoneally atthe dose of 25 14g per gram of body weight. Brains 
from the treated mice were examined at 24 hr after the administration. Please note that the 13-galactosidase-positive (C) and GFAP-positive (D) 
cells surround the blood vessels in the hippocampus. (E) and (F) show the CA1 region in coronal sections labeled for S-100. Astrocytes of Gfap -~- (E) 
and Gfap ÷'+ (F) mice were intensively stained (indicated by arrowheads), whereas some neurons in the pyramidal cell layer were weakly stained. 
(G) and (H) illustrate the molecular and granule c ll layers of cerebellum labeled for vimentin. Processes of Bergmann glia of both genotypes in 
the molecular layer show immunoreactivity. The sections were lightly counterstained with hematoxylin to indicate nuclei. Bars, 50 I~m (A, B, and 
E-H), 100 p.m (C and D). 
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Figure 3. lacZ Expression during Develop- 
ment of Gfap ÷ Mutant Mice 
(A) Dorsal view of whole brain from a Gfap -l- 
mutant mouse at embryonic day (ED) 17.5. 
Weak lacZ expression is first detectable in the 
paraventricular regions of the lateral, third, and 
fourth ventricles (arrowheads). 
(B) Ventral view of whole brain from a Gfap -l- 
mutant mouse at ED 18.5. lacZ expression is 
observed in the optic nerve (OP), medulla ob- 
Iongata (ME), and spinal cord (SP). 
(C and D) Medial (C) and lateral (D) views of a 
brain from a Gfap -/- mouse at postnatal day 15. 
lecZ is expressed in all brain regions and is 
especially strong inthe pia mater, medulla ob- 
Iongata, spinal cord, midbrain, corpus callo- 
sum, and cerebellar white matter. Bars, 2.5 
mm. 
grow up normally and are healthy at least up to the age 
that we have studied them (14 months). Both male and 
female Gfap -/- mice are fertile. 
To confirm that the mutation introduced into the Gfap 
gene abolishes GFAP synthesis, littermates were sub- 
jected to Northern, immunoblot, and immunohistochemi- 
cal analyses. Northern analysis detected no Gfap mRNA 
in the brain of Gfap -/- mice (data not shown). Immunoblot 
analysis of lysates from cerebrum, cerebellum, and spinal 
cord demonstrated the absence of GFAP in Gfap -/- mice 
and a reduced level of GFAP in Gfap +/- mice compared 
with Gfap +/+ mice (Figure 1C). Representative data of im- 
munohistochemical nalysis are shown in Figure 2. Stain- 
ing with anti-GFAP monoclonal antibody displayed the typ- 
ical pattern of astrocytes in the brains of Gfap +/÷ mice 
(Figure 2B), whereas no staining was observed in Gfap -l- 
mice (Figure 2A). The data represented were obtained with 
a monoclonal antibody (GF12.24). Similar results were 
also obtained by using another monoclonal (6F2) and rab- 
bit polyclonal antibodies in both immunoblot and immuno- 
histochemical analyses. These results clearly demon- 
strate the complete lack of GFAP in the Gfap -/- mice. 
Development of Astrocytes Devoid of GFAP 
To analyze the development of astrocytes in the mutant 
mice lacking GFAP, we ontogenetically followed the ex- 
pression of lacZ in the mutant mice. Several studies have 
shown that GFAP is first detectable during late embryonic 
development and that its immunoreactivity increases post- 
natally (Sapirstein, 1983; Weir et al., 1984). Whole-mount 
lacZ staining was performed on entire embryos from days 
12.5 to 18.5 postcoitus. For postnatal 7-, 15-, and 20-day- 
old and 6-week-old mice, the brain and spinal cord were 
stained. As shown in Figure 3, lacZ expression was first 
detected in the paraventricular regions of the lateral, third, 
and fourth ventricles on embryonic day (ED) 17.5 (Figure 
3A). At ED 18.5, the optic nerve, medulla oblongata, and 
spinal cord expressed lacZ (Figure 3B). After birth, lacZ 
was expressed in many other regions of the brain, with 
strong expression in the pia mater, optic nerve, corpus 
callosum, medulla oblongata, spinal cord, and cerebellar 
white matter (Figures 3C and 3D). 15-Galactosidase activity 
declined in the brains of adult mice. The expression pat- 
tern correlated well with that of GFAP in Gfap +/- mice (data 
not shown), indicating the usefulness of I~-galactosidase 
activity as a marker for GFAP-deficient astrocytes. How- 
ever, 13-galactosidase activity was slightly detectable by 
microscopy in cells scattered in most parenchymal re- 
gions. This seemed to be caused by diffusion of low 
amounts of I~-galactosidase while preparing sections. 
When the mice were treated with kainic acid, 13-galacto- 
sidase activity was strongly induced in mutant astrocytes, 
particularly in the hippocampus. Some cells expressing 
13-galactosidase surrounded the capillaries (Figure 2C), as 
normal astrocytes do (Figure 2D). Staining with an anti- 
body against S-100, another marker protein for astrocytes 
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Figure 4. IF Proteins Expressed in the Optic 
Nerve and Brain of Gfap-; Mice 
SDS-polyacrylamide g l (10.5O/o) of total pro- 
tein (lanes 1, 3, 5, and 7) and Triton-insoluble 
IF extracts (lanes 2, 4, 6, and 8) from the optic 
nerve and whole brain of Gfap ;- (lanes 1, 2, 
5, and 6) and Gfap +1+ (lanes 3, 4, 7, and 8) mice. 
The gel was stained with Coomassie blue. Posi- 
tions of NF200, NF145, NF68, vimentin (V), and 
GFAP (G) are indicated on the right. The arrow- 
head indicates the 62 kDa protein. The size 
markers (in kilodaltons) are indicated on the 
left. 
(Ludwin et al., 1976), also revealed that the distribution 
of the mutant astrocytes was similar to that of normal 
astrocytes (Figure 2E and 2F). Bergmann glia in the 
cerebellum, which express vimentin as well as GFAP in 
Gfap ÷~÷ mice, were also stained with anti-vimentin a tibody 
in Gfap + mice. The shape and immunoreactivity of the 
processes of mutant Bergmann glia did not seem to be 
altered (Figures 2G and 2H). These results suggest that 
the development and localization of astrocytes are not sig- 
nificantly hampered by the lack of GFAP. 
No Evidence for Compensatory Expression 
of Abnormal IF Proteins in Astrocytes 
of Gfap + Mice 
To determine whether some other IF proteins are synthe- 
sized to take the place of GFAP in the mutant astrocytes, 
we analyzed cytosketetal proteins, which are insoluble in 
nonionic solvent (Triton X-100), isolated from the optic 
nerves and whole brains of Gfap -/- mice by SDS-polyacryl- 
amide gel electrophoresis (SDS-PAGE; Figure 4). The op- 
tic nerve is the tissue with the highest abundance of 
astrocytes. A Triton-insoluble fraction from optic nerve of 
Gfap +~÷ mice contained the neurofilament triplets (200 kDa 
NF, 145 kDa NF, and 68 kDa NF), 57 kDa vimentin, and 
60 kDa GFAP. The identities of these proteins were con- 
firmed by immunoblot analysis (data not shown). In addi- 
tion to these proteins, a protein of 62 kDa was detected. 
The identity of this molecule is not yet clear; however, 
amino acid analysis indicated a similarity to the fourth neu- 
rofilament of 66 kDa identified in rat (Chiu et al., 1989; 
data not shown). This protein was hardly detectable in 
cultured astrocytes (data not shown), suggesting that it is 
specific to neurons. The fraction from Gfap -~- mice con- 
tained all of these proteins except GFAP. Several faint 
bands were observed in addition to molecules described 
above, but we did not observe quantitative differences in 
any proteins between mutant and wild-type fractions ana- 
lyzed. Similar results were obtained with whole-brain ex- 
tracts (Figure 4). 
Consistently, anti-cytokeratins and anti-desmin antibod- 
ies showed no immunoreactivity in astrocytes of mutant 
mice. Together, these results render it unlikely that the 
lack of GFAP leads to the compensatory expression of 
alternative IF protein(s) in astrocytes of Gfap + mice. 
Normal Development of CNS in Gfap + Mice 
Several lines of evidence from in vitro studies have sug- 
gested direct interactions between neurons and astrocytes. 
Furthermore, both cell types develop from a common pro- 
genitor. Therefore, the mutation of Gfap may alter the de- 
velopment of neurons. However, we found no apparent 
histological differences in brain architecture between 
Gfap + mutant and wild-type mice. Immunohistology with 
antibodies against actin, c(-tubulin, neurofilaments, micro- 
tubule-associated protein 1 (MAP1), neural cell adhesion 
molecule (N-CAM), and CNPase also failed to reveal any 
detectable abnormality (data not shown). Cell numbers in 
tempolateral cortex and thalamus counted at different 
ages (15-day-old and 6-, 16-, and 36-week-old) were similar 
in Gfap -~- and Gfap +/+ mice (data not shown). 
To evaluate the function of BBB, peroxidase trace exper- 
iments (Reese and Karnovsky, 1967) were performed in 
Gfap -/- mutant and Gfap÷/+mice. Horseradish peroxidase 
or microperoxidase was injected intravenously, and the 
brains were subsequently fixed and sliced. Then, the ex- 
travasation of peroxidase was detected by diaminobenzi- 
dine reaction. No leakage of peroxidase was observed 
with light or electron microscopic analysis in the brains of 
Gfap -/- mutant mice (data not shown), except for the re- 
gions in which leakage is commonly observed in the nor- 
mal brain, such as the paraventricular region of the third 
ventricle. This result suggests that deficiency of GFAP in 
astrocytes does not interfere with the establishment and 
maintenance of the BBB. 
From these results, it appears that the Gfap gene is not 
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Table 1. Summary of Scrapie Infection Experiments inGfap -/-, Gfap */-, and Gfap +/÷ Mice 
Susceptibility oScrapie Prion 
Prion Titers in Brains of Inoculated Mice 
(Log LD~g) 
No. of M ice  Appearance of Survival Days 
Genotype Inoculated a Symptom (days) (mean ± SD) 2 wks 12 wks 20 wks 
Gfap ÷/+ 14 143-153 175 _ 2 <3.0 d 7.35 7.85 
(10) (_)b (-)° NB ND ND 
Gfap +/- 21 143-153 172 ± 3 <3.0 7.39 7.89 
(12) (-) (-) ND ND NO 
Gfap -/- 15 143-153 175 ± 2 <3.0 e 6.98 7.83 
(10) (-) (-) ND ND ND 
ICR/SIc 3 143 176 ± 2 ND ND ND 
a Numbers of mice inoculated with a dose (102.~ LDs0 per animal) of mouse-adapted Obihiro strain of scrapie prion (Shinagawa et al., 1985). 
Parentheses indicate the number of mice inoculated with extract from brains of normal mice as a mock inoculation. 
b Minus sign indicates no appearance of disease during the observation period. 
c Minus sign indicates that all mice survived uring the observation period. The titers in brains recovered at 2, 12, and 20 weeks after inoculation 
(wks) were determined according to the procedure described by Prusiner et al. (1982). 
d One of 5 mice inoculated eveloped symptoms at 290 days. 
One of 5 mice inoculated eveloped symptoms at 220 days. ND, not determined. 
essential for the development and basic functions of the 
murine CNS. 
Inoculation of Scrapie Prion (PrP sc) 
in Gfap + Mutant Mice 
Gfap -/-, Gfap +/-, and Gfap ÷/÷ mice (7- to 8-week-old) were 
inoculated intracerebrally with a dose (102.8 LDso per ani- 
mal) of mouse-adapted Obihiro strain of scrapie prion 
(prps°; Shinagawa et al., 1985). The genetic background 
of Gfap -/-, Gfap +/-, and Gfap +/+ mice is derived from 129/ 
Ola and C57BL/6J strains. The 129 and C57BL/6 strains 
have the haplotype a of priori protein gene (Prn-p a) alleles, 
which causes a short scrapie incubation period (Carlson 
et al., 1988). As a control, ICR/SIc mice, a strain used for 
the determination ofprion titer, were inoculated with PrP so. 
The mice were sacrificed at 2, 12, 20, and 23 weeks after 
inoculation for histological and biochemical analyses. As 
a control, mice mock-infected with lysates from normal 
mouse brains were also examined in the same manner 
(Table 1). 
ICR/SIc mice first showed typical neurological symp- 
toms at 143 days of inoculation and died at 176 _.+ 2 days. 
Similarly, Gfap -/-, Gfap ÷/-, and Gfap +/+ mice first showed 
the neurological symptoms at 143-153 days and died at 
175 _ 2, 172 -4- 3, and 173 -4- 4days, respectively(Table 
1). No striking differences were observed in the neurologi- 
cal symptoms displayed by these three different geno- 
types. 
For the detection of scrapie prion (prpsc), extracts were 
prepared from brains of infected mice, and immunoblot- 
ting was performed using polyclonal anti-prion protein 
(PrP) antiserum obtained by immunization of a rabbit 
against a synthetic peptide corresponding to amino acids 
213-226 of mouse PrP (Yokoyama et al., unpublished 
data). The proteinase K-resistant PrP sc was detected in 
all mouse brain extracts 20 weeks after inoculation (data 
not shown). For the immunohistochemical detection of PrP 
amyloid plaques, tissue sections were stained with the 
above antibody. PrP amyloid plaques were found in vari- 
ous regions of the brain, such as the cerebral cortex, cor- 
pus callosum, hippocampus, and thalamus, both in 
scrapie-infected Gfap -/- and Gfap +/÷ mice (Figures 5A and 
5B). No plaques were observed in mock-infected brains. 
At 2, 12, and 20 weeks after inoculation, brains from 
2-4 mice were sampled and used for the infectivity titration 
assay. The samples were homogenized in phosphate- 
buffered saline (PBS), and a pool of the extracts was inocu- 
lated intracerebrally into 5-7 ICR/SIc mice per group. Sig- 
nificant propagation of infectious units was detected in 
Gfap -/- mice as well as Gfap +/- and Gfap +/+ mice by 12 
weeks of inoculation (Table 1). We did not observe signifi- 
cant differences in infectivities from the three genotypes. 
These data reveal that GFAP-deficient mice are as sus- 
ceptible to scrapie prion as normal mice, and that GFAP 
molecules do not significantly affect the propagation of 
PrP sc in the brain of mice. 
Astrocytic Responses in Scrapie-lnfected Gfap -l- 
Mutant Mice 
To evaluate the scrapie-induced neuropathology, brains 
of scrapie-infected and mock-infected Gfap -/- and Gfap +~÷ 
mice were analyzed histologically. Both scrapie-infected 
Gfap -/- and Gfap +/÷ mice showed vacuolative changes 
(spongiform degeneration typical of scrapie encephalopa- 
thy) in the cortex (Figures 5E and 5F), hippocampus (Fig- 
ures 51 and 5J), and thalamus (data not shown) at 20 and 
23 weeks after infection. Scrapie-infected Gfap ÷/+ mice 
showed remarkable reactive astrocytosis as detected by 
immunostaining with an anti-GFAP antibody (Figures 5F 
and 5J). Since the same staining gave rise to no signal 
in Gfap -/- mice (Figures 5E and 51), the reactive response 
of mutant astrocytes in Gfap -/- mice was evaluated by lacZ 
staining. Figure 6 shows 13-galactosidase activities in the 
brains of scrapie-infected and mock-infected Gfap -/- mice 
at 2, 12, 20, and 23 weeks after inoculation. A significant 
induction of 13-galactosidase activity was first observed at 
12 weeks after infection (in hippocampus and thalamus; 
Figure 6, arrows), and the activity increased dramatically 
by 23 weeks after infection (Figures 5E and 51; Figure 6). 
Vimentin is known to be expressed in reactive astrocytes 
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Figure 5. Histopathology of Brains from Gfap -/~ and Gfap ÷/÷ Mice Infected with Scrapie 
Gfap -/- mutant (A, C, E, G, and I) and Gfap +/* (B, D, F, H, and J) mice at 23 weeks after inoculation. PrP amyloid plaques in the cerebral cortex 
of Gfap/-  (A) and Gfap +/÷ (B). Peroxidase immunohistochemistry was performed with an antiserum obtained by immunization of rabbit with the 
synthetic peptide that corresponds to amino acids 213-226 of mouse PrP. Double staining for GFAP and 13-galactosidase was performed on the 
tempolateral cortex of cerebrum (C-F) and CA1 region of hippocampus (G--J). The vacuolative changes were observed in the cortex and hippocampus 
of scrapie-infected Gfap ÷ and Gfap */* mice (E, F, I, and J). In mock-infected Gfap +/÷ mice, scattered astrocytes with slender GFAP-positive processes 
are observed (D and H), whereas numerous reactive astrocytes with hypertrophic ytoplasm and strongly GFAP-positive processes were observed 
in scrapie-infected Gfap +/+ mice (F and J). In Gfap -/- mice, an increased expression of lacZ in the cortex and hippocampus occurs in scrapie-infected 
(E and I) brain. No GFAP immunoreactivity was detected in mock-infected (C and G) or scrapie-infected (E and I) brains from mutant mice. The 
sections were lightly counterstained with hematoxylin. Bars, 50 ~tm (A and B), 100 ~m (C-H). 
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Figure 6. lacZ Expression in Brains from Scrapie-lnfected Gfap ÷ 
Mice 
Coronal brain sections through the hippocampal nd thalamic regions. 
Mock-infected (Mock) and scrapie-infected (Scrapie) brains at 2, 12, 
20, and 23 weeks after inoculation are aligned in the left and right 
columns, respectively. Increased lacZ expression was first evident in 
the hippocampus and thalamus 12 weeks after infection (i dicated 
by arrows). By 23 weeks after scrapie infection, the 13-galactosidase 
activity had increased ramatically in a wide area of the brain regions. 
(Dahl et al., 1981; Pixley and de Vellis, 1984; Schiffer et 
al.,1986; Petito et al., 1990), in contrast o most astrocytes 
under physiological conditions. Therefore, we analyzed 
the astrocytic reactivity in scrapie-infected Gfap -/- mice 
by vimentin immunocytochemistry. Moderate vimentin im- 
munoreactivity was observed in the cytoplasm of reactive 
astrocytes of scrapie-infected Gfap +/÷ mice (Figure 7A). 
Immunoreactivity against S-100 protein, a marker for 
astrocytes, was also detected in reactive astrocytes of 
scrapie-infected Gfap ÷/+ mice (Figure 7C). In Gfap -/- mice, 
13-galactosidase-positive mutant astrocytes were cola- 
beled with anti-vimentin and anti-S-100 antibodies (Fig- 
ures 7E and 7F), indicating their astrocytic identity. How- 
ever, the immunostaining of vimentin and S-100 protein in 
Gfap -/- astrocytes was slightly different from that of Gfap ÷/÷ 
reactive astrocytes (compare Figures 7A and 7B for vimen- 
tin and Figures 7C and 7D for S-100). Vimentin signals 
are filamentous and fill the cytoplasms of Gfap ÷/+ reactive 
astrocytes (Figure 7A). In contrast, vimentin signals in mu- 
tant astrocytes tend to be granular and scarce around the 
nuclei (Figure 7B). S-100 protein is normally localized to 
the nuclei and cytoplasm of reactive astrocytes (Figure 
7C). The anti-S-100 antibody strongly stained the nuclei of 
the astrocytes of Gfap -~- (Figure 7D) as well as Gfap +~+ mice. 
However, similar to anti-vimentin staining, S-100 signals 
are scarce in the cytoplasm of mutant astrocytes, particu- 
larly around the nuclei (Figure 7D). 
In agreement with the immunohistochemistry, immu- 
noblot analysis clearly showed an increase of GFAP and 
vimentin in the brains of scrapie-infected Gfap ÷~÷ mice 20 
weeks after inoculation. In the brains of scrapie-infected 
Gfap -~- mice, increased vimentin expression was also de- 
tected by immunoblotting (data not shown). 
These results show that scrapie-specific neuropathol- 
ogy is induced in the brain of Gfap-~-mice. Furthermore, 
they suggest that GFAP is not essential for the induction 
of reactive astrocytosis. 
Discussion 
In the present study, we disrupted the Gfap gene in mice 
by replacing a short fragment of the first exon with the 
lacZ gene using ES cell technology. GFAP expression in 
astrocytes is thought o be important for the morphogene- 
sis and structural support of the CNS. However, mutant 
mice devoid of GFAP exhibit no obvious defects in devel- 
opment and tissue architecture in the CNS. Astrocytes 
lacking GFAP have a normal distribution, and the mutation 
did not result in any detectable deficiency of neuronal de- 
velopment. Additionally, the mutant astrocytes extend 
their processes to capillaries as normal cells do. Electron 
microscopic analysis and peroxidase permeability ests 
showed that the BBB is structurally normal in Gfap -I- mu- 
tant mice (data not shown). 
The lack of any apparent defects in the mutant mice 
suggests that GFAP does not have an essential role in 
the development of astrocytes. Astrocytes are known to 
be heterogeneous in cell shape and probably in function. 
Some astrocytes do not contain detectable amounts of 
GFAP in vivo. Given the fact that the null mutation in the 
Gfap gene does not induce compensatory expression of 
alternative IF proteins the data may suggest that no IF 
proteins are required for the physiology of some types of 
astrocytes. Very recently, vimentin knockout mice were 
generated (Colucci-Guyon et al., 1994). The mice devoid 
of vimentin have not shown any apparent defects. As in 
the case of GFAP, there was no evidence for the compen- 
satory expression of alternative IF proteins in the vimentin- 
deficient mice, and a complete lack of any IF networks in 
vivo was observed in the lens fibers from these mutant 
mice. 
Even though the above interpretation is true for some 
astrocytes, it is also possible that some other molecule(s) 
functionally compensate for the lack of GFAP. In the 
course of astrocyte development, a transition in expres- 
sion of IF protein genes has been observed (Hockfield and 
McKay, 1985; Lendahl et al., 1990; Fliegner and Liem, 
1991 ; Liem, 1993). Proliferating neuroepithelial stem cells, 
which can differentiate into neurons and glia, express vi- 
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Figure 7. Astrocytic Changes Shown by Vimentin andS-100 Staining in the Brains of Gfap ÷ and Gfap +/+ Mice Infected with Scrapie 
Mice brain sections at 23 weeks after scrapie inoculation. Vimentin immunoreactivity is shown in the cytoplasm (A), whereas S-100 immunoreactivity 
is located in both the cytoplasm and the nucleus (C) of reactive astrocytes in Gfap +~÷ mice. Please note in Gfap -~- mice, vimentin immunoreactivity 
is granular (B), and S-100 immunoreactivity is strong in the nucleus but not in the cytoplasm (D). In Gfap-"- mice, lacZ-expressing cells show 
vimentin (E) and S-100 (F) immunoreactivities (arrows). The sections were lightly counterstained with hematoxylin. Bars, 20 p.m (A-D), 25 ~m (E 
and F). 
mentin and nestin (Frederiksen and McKay, 1988; Lendahl 
et al., 1990). Radial glial cells that differentiate into CNS 
astrocytes (Schmechel and Rakic, 1979) express both vi- 
mentin and nestin (Hockfield and McKay, 1985). GFAP- 
negative and vimentin-positive radial glia of rat disappear 
at an early postnatal stage, whereas the expression of 
GFAP in mature astrocytes dramatically increases be- 
tween birth and postnatal day 20 (Pixley and de Vellis, 
1984). Nestin is absent in astrocytes from adult brain, 
whereas vimentin is constitutively expressed in some ma- 
ture astrocytes, such as the astrocytes in the optic nerve, 
Bergmann glial cells in cerebellum, and white matter 
astrocytes in the adult brain (Schnitzer et al., 1981; Yoko- 
yama et al., 1981; Pixley et al., 1984; Pixley and de Vellis, 
1984). Furthermore, vimentin is induced in reactive astro- 
cytes following neuronal damage (Dahl et a l ,  1981; Pixley 
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and de Vellis, 1984; Schiffer et al., 1986; Petito et al., 
1990) and in in vitro-cultured astrocytes, suggesting that 
the Vim locus is not completely silent in mature astrocytes, 
in which vimentin is hardly detectable in vivo. Therefore, 
vimentin may in part compensate for the lack of GFAP. 
Very small amounts of vimentin could be sufficient for the 
putative functional compensation. The hypothesis dis- 
cussed above should be tested by generating double 
knockout mice for GFAP and vimentin. 
Since the IF proteins comprise a very large gene family, 
more unidentified IF proteins may be involved in the puta- 
tive compensation. Indeed, a monoclonal antibody (34C9) 
that reacts with an epitope of human epidermal keratin has 
been demonstrated to bind to a cytoskeletal fiber structure 
closely associated with GFAP in a subclass of astrocytes 
of the adult hamster brain and in astrocytes in fetal mouse 
brain cultures (Franko et al., 1987). In immunoblot analy- 
sis, the 34C9 monoclonal antibody was shown to recog- 
nize a 65 kDa protein (p65) and not to recognize GFAP. 
This observation suggests that epidermal keratins share 
an epitope not only among themselves but also with a 
keratin in neuronal tissue. The p65 might be a restricted 
IF protein that copolymerizes with GFAP. Alternatively, it
could be an IF-associated protein. This protein is another 
candidate molecule that may compensate for the lack of 
GFAP. 
GFAP accumulation in reactive astrocytes has been ob- 
served in scrapie-infected brain (Mackenzie, 1983; Wiet- 
grefe et al., 1985; Kretzschmar et al., 1986; B0e!er et al., 
1993) and human brain with Creutzfeldt-Jakob disease 
(Hirano et al., 1972). Interestingly, previous biochemical 
studies by Oesch et al. (1990) showed a high affinity of 
PrP s° or its cellular form, PrP c, to GFAP. It was therefore 
important o determine whether GFAP has a role in the 
pathogenesis of prion diseases. In this study, Gfap -/- mice 
infected with PrP s~ showed the same scrapie-specific neu- 
ropathology and the same disease time course as did 
scrapie-infected Gfap +/÷ mice. Our results revealed that 
Gfap -/- mice have a normal susceptibility to scrapie infec- 
tion and are unaffected in the propagation of PrP sc. These 
results indicate that GFAP is not crucial for scrapie- 
induced neuropathogenesis. However, we cannot exclude 
the possibility that the interaction between GFAP and PrP c 
is physiologically required for astrocytic functions, and in 
turn for some neuronal activities. PrP c mRNA and protein, 
abundantly expressed in neurons, have been detected in 
many cell types, including astrocytes (Kretzschmar et al., 
1986; DeArmond et al., 1987; Brown et al., 1990; Cashman 
et al., 1990). Interestingly, ithas been shown recently that 
hippocampal slices from PrP null mutant mice have weak- 
ened y-aminobutyric acid type A receptor-mediated fast 
inhibition and impaired long-term potentiation (Collinge et 
al., 1994). The remaining issue could be tested by analyz- 
ing the cumulative effects on these activities in double 
knockout mice for GFAP and PrP. 
The scrapie prion is known to be a strong inducer of 
reactive astrocytes. The progression of the prion diseases 
results in typical reactive astrocytosis. The reactive astro- 
cytes are histologically characterized by cytoplasmic hy- 
pertrophy associated with profusion of long and thick pro- 
cesses filled with GFAP, and often by enlarged and 
irregularly outlined nuclei. Astrocytes devoid of GFAP in 
Gfap -/- mutant mice showed increased lacZ expression 
along with the progression of disease, correlating with ac- 
cumulation of GFAP in wild-type mice. Increased expres- 
sion of vimentin was also detected in the astrocytes of 
mutant as well as wild-type mice by immunoblot and immu- 
nocytochemical analysis. These results suggest that the 
astrocytes devoid of GFAP are able to be transformed to 
a reactive state, and that the 13-galactosidase activity in 
the mutant astrocytes is a useful marker for the reactive 
state. The 13-galactosidase activity may reflect the Gfap 
gene transcriptional ctivity better than the level of GFAP 
protein itself, whose stability could be altered by polymer- 
ization. Therefore, the mutant mice generated here may 
provide a useful tool to analyze the induction mechanisms 
for reactive responses of astrocytes. 
The mutant astrocytes from scrapie-infected mice showed 
subtle differences from wild-type reactive astrocytes in 
stainability with anti-S-100 and anti-vimentin antibodies. 
The mutant astrocytes did not seem to have the normal 
cytoplasmic localization of these molecules. S-100 pro- 
tein, which is a calcium-binding, glial-specific protein, is 
known to bind to GFAP and prohibit its polymerization i  
vitro (Bianchi et al., 1993). Vimentin is known to copolymer- 
ize with GFAP (Quinlan and Franke, 1983; Wang et al., 
1984). Therefore, it is not surprising that the lack of GFAP 
might have altered the subcellular localization and/or poly- 
merization of these molecules. The consequences of 
these observations are not yet known. However, if the sub- 
cellular distribution of these and other molecules were al- 
tered in astrocytes under normal physiological conditions, 
the mutation might alter the physiological functions spe- 
cific for astrocytes. Additional electrophysiological nd 
biochemical studies are required to analyze this issue 
further. 
Experimental Procedures 
Construction of the Targeting Vector 
A genomic DNA clone of mouse GFAP was isolated from a 129/Sv 
genomic library by screening with a mouse DNA fragment previously 
amplified by polymerase chain reaction. The fragments used were a 
2.0 kb SaU fragment of the promoter region, a 3.5 kb Sacl fragment 
from exon 1 to intron 1, a 3.7 kb HindllI-BamHI lacZ gene fragment 
prepared from pCH110 (Pharmacia), a1.8 kb pgk-neo gene cassette 
derived from pKJ 1 (McBurney et al., 1991; a gift from Michael A. Rud- 
nicki), and a 1.0 kb XhoI-Sall diphtheria toxin A-fragment (DT-A) gene 
cassette derived from pMC1DT-A (Yagi et al., 1990; a gift of Shinichi 
Aizawa). The resulting construct could transcribe the lacZ gene from 
the GFAP promoter and abolish the transcription ofthe Gfap gene. 
Targeting Experiments 
The ES cell line used was E14 (Hooper et al., 1987). Cell culture and 
the targeting experiment were carried out as described previously 
(Itohara et al., 1993). In brief, 5 x 107 ES cells were electroporated 
with a Bio-Rad Gene Pulser (800 V and 3 mF in a 0.4 cm electrode 
distance) using 30 p.g of DNA. Prior to electroporation, the targeting 
vector was linearized by digestion with Notl. The electroporated cells 
were plated in ten 10 cm dishes coated with mitotically inactivated 
embryonic fibroblasts derived from the TCR 8 gene knockout mice 
(Itohara et al., 1993). G4t8 was added 24 hr after electroporation, and 
colonies were picked at day 7 of selection into wells of 96-well plates. 
The cells were cultured and passaged into 24-well plates, and half of 
the cells were stored in liquid nitrogen until the completion of screen- 
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ing. The other half of the cells were screened by digestion with Sacl 
or BamHI and hybridization with a 5' external probe (5' probe; a 0.5 
kb SacI-Ball fragment) or a 3'external probe (3'probe; a 0.4 kb Hindlll- 
BamHI fragment). Southern blots were analyzed using a Fujix Bio- 
Image Analyzer BAS2000. 
Generation of Chimeric Mice and Screening of Mutant Mice 
Chimeras were generated as described (Bradley, 1987). ES cells (15- 
20) were microinjected into C57BL/6J blastocysts at 3.5 days post- 
coitum. After injection, the embryos were transferred into the uteri 
of pseudopregnant ICR mice. Mice heterozygous for the mutation 
(Gfap +/-) were obtained by crossing the chimeras to C57BL/6J mice. 
The heterozygotes (Gfap +/-) were further intercrossed to obtain muta- 
tion homozygotes (Gfap/-). The genotypes of the mice were deter- 
mined by Southern blot analysis of DNA prepared from tails, as men- 
tioned above. 
Histological Analysis 
For lacZ staining of brain and spinal cord, mice were anesthetized 
with Nembutal, and brains were fixed by immersion or intracardiac 
perfusion with fixative solution containing 2% formaldehyde, 2 mM 
MgCI2, and 1.25 mM EGTA in 0.1 M PIPES (pH 6.9), followed by perfu- 
sion with PBS at 4°C. Samples were washed three times in 50 mM 
phosphate buffer (pH 7.3) and stained at 37°C overnight in a solution 
containing 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)8, 2 mM MgCI2, 0.02% 
Nonidet P-40, 0.01% sodium deoxycholate, and 1 mg/ml X-gal (5-bromo- 
4-chloro-3-indoyl-[~-D-galactcpyranoside) in the phosphate buffer. 
For paraffin sections, fresh samples were fixed with neutral buffered 
formalin or ethanol, and lacZ-stained samples were postfixed in 2% 
formaldehyde in the phosphate buffer, dehydrated, and embedded in 
paraffin. Sections (4 pm) were used for hematoxylin-eosin and immu- 
nohistochemical staining. 
The immunohistochemical detection was performed with an avidin- 
biotin-peroxidase technique using the Vectastain ABC kit (Vector 
Lab.) following the manufacturer's instructions. Anti-GFAP (GF 12.24), 
anti-vimentin (VIM 3B4), and anti-cytokeratin 8 (Ks 8.7) and 18 (Ks 
18.4) monoclonal antibodies were purchased from Progen Biotechnic. 
Another anti-GFAP monoclonal (6F2) and rabbit anti-GFAP polyclonal 
antibodies were purchased from Monosan. Monoclonal antibodies to 
neurofilament 68 kDa, 145 kDa, and 200 kDa subunits were purchased 
from Transformation Research Inc. Anti-S-100 protein (15E2) and anti- 
actin monoclonal antibodies were purchased from Chemicon Interna- 
tional Inc. Anti-vimentin (vg), anti-desmin (DE-U-10), anti-(x-tubulin 
(DM 1A), anti-CNPase (11-5B), anti-N-CAM (NCAM-OB11), and anti- 
MAP1 (HM-1) monoclonal antibodies were purchased from Sigma. 
Biochemical Analysis 
Mouse brain extracts were analyzed by SDS-PAGE (Laemmli, 1970) 
and immunoblotting. The cerebrum, cerebellum, spinal cord, and optic 
nerves were homogenized in lysis buffer (50 mM sodium phosphate 
(pH 7.3), 2 rnM EDTA, 2 mM EGTA, 0.5 rnM TPCK, 0.8 mM phenylmeth- 
ylsulfonyl fluoride [PMSF]), and an equal volume of 2x SDS-sample 
buffer (0.25 M Tris-HCI [pH 6.8], 2o/0 SDS, 50o/0 glycerol, 10% 
2-mercaptoethanol) was added. Protein (10 pg) was electrophoresed 
on 10.5% polyacrylamide gels and blotted on an Immobilon-P mem- 
brane (Milipore). After blocking the membrane with 5% skim milk in 
Tris-buffered saline, the blots were immersed sequentially in mouse 
monoclonal primary antibodies (1:50 to 1:300) and peroxidase- 
conjugated rat anti-mouse IgG (1:5000; Zymsd Laboratories Inc.) and 
developed in ECL Western blotting detection reagent (Amersham). 
Triton-insoluble cytoskeletal proteins from optic nerve and brain 
were prepared as described by Pruss et al. (1981). The tissues were 
homogenized with ice-cold PBS consisting of 171 mM NaCI, 6 mM 
sodium phosphate (pH 7.4), 3 mM KCI, 2 mM EDTA, 2 mM EGTA, 
and 1 mM PMSF. This homogenate was centrifuged at 8000 x g for 
10 rain at 4 °C, and the pellet was extracted with an extraction buffer 
containing 171 mM NaCI, 6 mM sodium phosphate (pH 7.4), 600 mM 
KCI, 0.5% (w/v) Triton X-100, 1 mM EDTA, 1 mM EGTA, and 1 mM 
PMSF. This homogenate was centrifuged again at 8000 x g for 10 
rain at 4°C, and the pellet was re-extracted twice with the extraction 
buffer. The final Triton-insoluble pellet was washed four times with 
ice-cold washing buffer containing 171 mM NaCI, 6 mM sodium phos- 
phate (pH 7.4), and 3 mM KCI. 
Inoculation of Scrapie Prion 
The Obihiro strain of scrapie prion (PrPSC), which has been passaged 
in ICR/SIc mice more than ten times (Shinagawa et al. 1985) was 
prepared from infected brains homogenized in PBS and intracerebrally 
inoculated (102.8 LDso/animal) into 7- to 8-week-old Gfap -/, Gfap +/-, 
and Gfap +/+ mice, Normal brain homogenates (10%) were used for 
mock infection experiments. As a further control, ICR/SIc mice were 
inoculated with PrP so. Mice were observed daily for the appearance of 
scrapie-associated symptoms, i,e., ataxia, ruffled hair, disorientation, 
and depression. Mice were examined histologically and biochemically 
at 2, 12, 20, and 23 weeks after inoculation. 
For biochemical analysis, PrP s: was purified by the procedure of 
Hilmert and Diringer (1984) with minor modifications to use a bench 
top ultracentrifuge Beckman Optima TL Briefly, brain samples were 
homogenized with 10 mM Tris buffer (pH 7.4) containing 10% sarcosyl 
and then centrifuged at 22,000 x g for 10 min, The supernatant was 
centrifuged at 540,000 x g for 30 rain. The resulting pellet was soni- 
cated in Tris buffer containing 1% sarcosyl and 10% NaCI and centri- 
fuged again at 540,000 x g for 30 rain. The pellet was treated with 
proteinase K (2 pg per gram of brain equivalent) at 37°C for 60 rain 
and centrifuged three times at 22,000 × g for 10 rain. The final pellet 
was subjected to SDS-PAGE (15% polyacrylamide gel). Immunoblot- 
ting was performed using polyclonal anti-prion protein (PrP) antiserum 
obtained by immunization of rabbit against the synthetic peptide that 
corresponds to the sequence at amino acids 213-226 (CVTQYQKES- 
QAYYD) of mouse PrP (Yokoyama et al., unpublished data). 
For the immunohistochemical detection of PrP amyloid plaques, 
tissue sections were deparaffinized, followed by dehydration and auto- 
claving (121 °C, 10 rain) in distilled water. Sections were reacted with 
the above-mentioned primary antibody at a 1:350 dilution and a sec- 
ondary anti-rabbit IgG using the Vectastain ABC kit. 
The infectivity in the brains of infected mice was determined ac- 
cording to a published procedure (Prusiner et al., 1982). Brain samples 
were homogenized in PBS at 10% or 1% (w/v). Mice were inoculated 
intracerebrally with 20 p.I of the homogenates. The procedure is based 
on the correlation between the titer and the incubation period. One 
of us (T. Y.) has confirmed the reliability of the assay by separate 
experiments. 
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